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 Mean (SD) and N (%) with adjustments for age where relevant and median (Q1, Q3) are shown by fifths of measured waist-to-hip ratio and GRS. 
 Mean (SD) and N (%) with adjustments for top 40 principal components and genotyping array and median (Q1, Q3) are shown by fifths of measured waist-to-hip ratio and GRS. 
¶ Diabetes is defined as self-reported diabetes or HbA1c  
§ Any vascular diseases include self-reported heart attack, angina, and stroke. 
 CKD was defined as long-term renal replacement therapy, or eGFRcys-cr<60 mL/min/1.73m2or urinary albumin:creatinine ratio  3 mg/mmol. 
Exclusions: relatedness, non-White British, self-reported cancer, chronic obstructive pulmonary disease or liver failure/cirrhosis; with missing values of genetic risk score, adiposity measures, blood pressure, or chronic kidney disease. 
Waist-to-hip ratio GRS included 394 SNPs (variance explained: 2.53%). 




 Fifths of measured waist-to-hip ratio   Fifths of genetic risk score for waist-to-hip ratio  
Men 
(n=132,536) Characteristics I II III IV V   I II III IV V 
Adiposity             
   Waist-to-hip ratio 
0.85 (0.02) 0.90 (0.02) 0.93 (0.02) 0.97 (0.02) 1.03 (0.02)  0.92 (0.06) 0.93 (0.06) 0.93 (0.06) 0.94 (0.06) 0.95 (0.06) 0.93 (0.06) 
   BMI (kg/m2) 
24.4 (3.4) 26.3 (3.4) 27.6 (3.4) 29.1 (3.4) 31.6 (3.4)  27.1 (4.1) 27.6 (4.1) 27.8 (4.1) 28.1 (4.1) 28.5 (4.1) 27.8 (4.2) 
Socio-demographics 
            
   Age, years 
54.5 (8.0) 55.9 (8.0) 56.9 (8.0) 57.8 (8.0) 58.8 (8.0)  56.8 (8.1) 56.8 (8.1) 56.8 (8.1) 56.8 (8.1) 56.7 (8.1) 56.8 (8.1) 
   College or University degree 
11,847 (43.7%) 9,990 (36.8%) 8,897 (33.0%) 7,431 (28.3%) 6,115 (23.4%)  9,566 (35.8%) 9,013 (33.9%) 8,890 (33.6%) 8,609 (32.5%) 8,202 (31.1%) 44,280 (33.4%) 
   Deprivation score 
-2.5 (-3.9, -0.2) -2.5 (-3.9, -0.3) -2.5 (-3.8, -0.1) -2.3 (-3.7, 0.2) -2.0 (-3.5, 0.9)  -2.4 (-3.8, -0.1) -2.4 (-3.8, 0.0) -2.4 (-3.8, 0.1) -2.3 (-3.7, 0.1) -2.3 (-3.7, 0.3) -2.4 (-3.8, 0.1) 
Lifestyle 
            
   Current smoker 
2,769 (9.8%) 2,961 (10.8%) 3,130 (11.7%) 3,142 (12.2%) 3,519 (14.0%)  2,947 (11.2%) 2,971 (11.3%) 3,079 (11.6%) 3,208 (12.1%) 3,316 (12.4%) 15,521 (11.7%) 
   Physical activity 
27.9 (13.7, 52.1) 24.5 (11.6, 48.2) 22.9 (10.3, 46.9) 20.6 (8.6, 44.0) 17.6 (7.3, 40.2)  22.4 (10.2, 45.9) 23.1 (10.1, 46.6) 23.0 (10.1, 47.1) 22.9 (9.9, 46.7) 22.8 (10.0, 47.3) 22.9 (10.0, 46.7) 
Health status 
            
   Diabetes ¶ 
557 (1.9%) 849 (2.7%) 1,369 (4.2%) 2,243 (6.8%) 4,350 (13.0%)  1,488 (5.6%) 1,713 (6.4%) 1,844 (6.9%) 1,962 (7.3%) 2,361 (8.8%) 9,368 (7.1%) 
   Any vascular diseases § 
1,103 (4.7%) 1,544 (5.9%) 1,979 (7.1%) 2,508 (8.6%) 3,540 (11.5%)  1,887 (7.1%) 2,045 (7.7%) 2,108 (7.9%) 2,268 (8.5%) 2,366 (8.9%) 10,674 (8.1%) 
SBP (mmHg) 
138 (17) 140 (17) 142 (17) 143 (17) 143 (17)  141 (17) 141 (17) 141 (17) 141 (17) 142 (17) 141 (17) 
DBP (mmHg) 
81 (10) 84 (10) 85 (10) 86 (10) 86 (10)   84 (10) 84 (10) 84 (10) 84 (10) 85 (10) 84 (10) 
CKD  
949 (3.8%) 1,111 (4.1%) 1,456 (5.0%) 2,001 (6.7%) 3,312 (10.8%)  1,629 (6.2%) 1,687 (6.4%) 1,772 (6.7%) 1,766 (6.6%) 1,975 (7.4%) 8,829 (6.7%) 




 Mean (SD) and N (%) with adjustments for age where relevant and median (Q1, Q3) are shown by fifths of measured waist-to-hip ratio and GRS. 
 Mean (SD) and N (%) with adjustments for top 40 principal components and genotyping array and median (Q1, Q3) are shown by fifths of measured waist-to-hip ratio and GRS. 
¶ Diabetes is defined as self-reported diabetes or HbA1c  
§ Any vascular diseases include self-reported heart attack, angina, and stroke. 
CKD was defined as long-term renal replacement therapy, or eGFRcys-cr<60 mL/min/1.73m2 or urinary albumin:creatinine 3 mg/mmol. 
Exclusions: relatedness, non-White British, self-reported cancer, chronic obstructive pulmonary disease or liver failure/cirrhosis; with missing values of genetic risk score, adiposity measures, blood pressure, or chronic kidney disease. 
Waist-to-hip ratio GRS included 394 SNPs (variance explained: 5.29%). 




 Fifths of measured waist-to-hip ratio   Fifths of genetic risk score for waist-to-hip ratio  
Women 
(n=148,692) Characteristics I II III IV V   I II III IV V 
Adiposity             
   Waist-to-hip ratio 
0.72 (0.02) 0.77 (0.02) 0.81 (0.02) 0.85 (0.02) 0.92 (0.02)  0.79 (0.07) 0.81 (0.07) 0.82 (0.07) 0.82 (0.07) 0.84 (0.07) 0.82 (0.07) 
   BMI (kg/m2) 
23.9 (4.5) 25.2 (4.5) 26.8 (4.5) 28.5 (4.5) 30.4 (4.5)  26.6 (5.0) 26.8 (5.0) 27.0 (5.0) 27.1 (5.0) 27.3 (5.0) 27.0 (5.0) 
Socio-demographics 
 
   Age, years 
54.2 (7.8) 55.5 (7.8) 56.5 (7.8) 57.3 (7.8) 58.1 (7.8)  56.4 (7.9) 56.4 (7.9) 56.3 (7.9) 56.3 (7.9) 56.4 (7.9) 56.3 (7.9) 
   College or University degree 
11,223 (35.9%) 10,048 (32.9%) 9,027 (30.5%) 8,026 (27.5%) 6,855 (24.1%)  9,497 (31.9%) 9,187 (30.8%) 9,107 (30.6%) 8,812 (29.7%) 8,576 (28.9%) 45,179 (30.4%) 
   Deprivation score 
-2.6 (-3.9, -0.5) -2.5 (-3.8, -0.4) -2.4 (-3.8, -0.2) -2.3 (-3.7, 0.1) -2.0 (-3.5, 0.7)  -2.4 (-3.8, -0.2) -2.4 (-3.8, -0.1) -2.4 (-3.7, 0.0) -2.4 (-3.8, -0.1) -2.3 (-3.7, 0.1) -2.4 (-3.7, 0.0) 
Lifestyle 
 
   Current smoker 
1,751 (5.3%) 2,292 (7.2%) 2,499 (8.3%) 2,833 (9.6%) 3,241 (11.4%)  2,333 (8.0%) 2,401 (8.1%) 2,545 (8.5%) 2,664 (8.9%) 2,673 (8.9%) 12,616 (8.5%) 
   Physical activity 
22.9 (11.0, 44.0) 22.0 (10.1, 42.0) 20.6 (9.3, 41.2) 19.1 (8.5, 39.2) 17.6 (7.8, 37.5)  20.4 (9.2, 40.6) 20.5 (9.2, 40.6) 20.7 (9.3, 41.6) 20.8 (9.3, 41.4) 20.2 (9.1, 40.6) 20.6 (9.2, 41.0) 
Health status 
 
   Diabetes ¶ 
293 (0.8%) 414 (1.0%) 600 (1.5%) 1,163 (2.8%) 2,987 (7.2%)  731 (2.4%) 940 (3.1%) 1,077 (3.5%) 1,216 (4.0%) 1,493 (4.9%) 5,457 (3.7%) 
   Any vascular diseases § 
415 (1.6%) 571 (1.9%) 790 (2.5%) 1,112 (3.2%) 1,732 (4.8%)  762 (2.6%) 884 (3.0%) 969 (3.2%) 965 (3.2%) 1,040 (3.5%) 4,620 (3.1%) 
SBP (mmHg) 
132 (18) 134 (18) 135 (18) 137 (18) 138 (18)  135 (19) 135 (19) 135 (19) 136 (19) 136 (19) 135 (19) 
DBP (mmHg) 
78 (10) 79 (10) 81 (10) 82 (10) 83 (10)   80 (10) 80 (10) 81 (10) 81 (10) 81 (10) 81 (10) 
CKD  
1,298 (4.7%) 1,474 (5.0%) 1,590 (5.2%) 1,989 (6.2%) 2,854 (8.7%)  1,718 (5.8%) 1,793 (6.0%) 1,834 (6.2%) 1,945 (6.5%) 1,915 (6.4%) 9,205 (6.2%) 
Supplemental table 2a: Baseline characteristics by fifths of measured BMI and genetic risk score (GRS) in men 
 
 Fifths of measured BMI   Fifths of genetic risk score for BMI  
Men 
(n=132,536) Characteristics I II III IV V   I II III IV V 
Adiposity             
   Waist-to-hip ratio 
   BMI (kg/m2) 
Socio-demographics 
   Age, years 
   College or University degree 
   Deprivation score 
Lifestyle 
   Current smoker 
   Physical activity 
Health status 
   Diabetes ¶ 




1,118 (4.0%) 1,235 (4.3%) 1,467 (5.1%) 1,820 (6.3%) 3,189 (11.4%)  1,495 (5.6%) 1,710 (6.4%) 1,749 (6.6%) 1,842 (6.9%) 2,033 (7.6%) 8,829 (6.7%) 
 
 Mean (SD) and N (%) with adjustments for age where relevant and median (Q1, Q3) are shown by fifths of measured BMI and GRS. 
 Mean (SD) and N (%) with adjustments for top 40 principal components and genotyping array and median (Q1, Q3) are shown by fifths of measured BMI and GRS. 
¶ Diabetes is defined as self-reported diabetes or HbA1c  
§ Any vascular diseases include self-reported heart attack, angina, and stroke. 
CKD was defined as long-term renal replacement therapy, or eGFRcys-cr<60 mL/min/1.73m2 or urinary albumin:creatinine ratio 3 mg/mmol. 
Exclusions: relatedness, non-White British, self-reported cancer, chronic obstructive pulmonary disease or liver failure/cirrhosis; with missing values of genetic risk score, adiposity measures, blood pressure, or chronic kidney disease. 
BMI GRS included 773 SNPs (variance explained: 6.14%). 
BMI: body mass index; CKD: chronic kidney disease; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; GRS: genetic risk score; HbA1c: glycosylated hemoglobin; SBP: systolic blood pressure. 
 
 
Supplemental table 2b: Baseline characteristics by fifths of measured BMI and genetic risk score (GRS) in women 
 
 Fifths of measured BMI   Fifths of genetic risk score for BMI  
Women 
(n=148,692) Characteristics I II III IV V   I II III IV V 
Adiposity             
   Waist-to-hip ratio 
   BMI (kg/m2) 
Socio-demographics 
   Age, years 
   College or University degree 
   Deprivation score 
Lifestyle 
   Current smoker 
   Physical activity 
Health status 
   Diabetes ¶ 




1,504 (5.3%) 1,378 (4.5%) 1,532 (4.8%) 1,872 (5.8%) 2,919 (9.4%)  1,743 (5.9%) 1,684 (5.7%) 1,877 (6.3%) 1,888 (6.3%) 2,013 (6.7%) 9,205 (6.2%) 
 
 Mean (SD) and N (%) with adjustments for age where relevant and median (Q1, Q3) are shown by fifths of measured BMI and GRS. 
 Mean (SD) and N (%) with adjustments for top 40 principal components and genotyping array and median (Q1, Q3) are shown by fifths of measured BMI and GRS. 
¶ Diabetes is defined as self-reported diabetes or HbA1c  
§ Any vascular diseases include self-reported heart attack, angina, and stroke. 
 CKD was defined as long-term renal replacement therapy, or eGFRcys-cr<60 mL/min/1.73m2 or urinary albumin:creatinine ratio 3 mg/mmol. 
Exclusions: relatedness, non-White British, self-reported cancer, chronic obstructive pulmonary disease or liver failure/cirrhosis; with missing values of genetic risk score, adiposity measures, blood pressure, or chronic kidney disease. 
BMI GRS included 773 SNPs (variance explained: 5.54%). 
BMI: body mass index; CKD: chronic kidney disease; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; GRS: genetic risk score; HbA1c: glycosylated hemoglobin; SBP: systolic blood pressure. 
 
 
Supplemental table 3a: Conventional and genetic associations between adiposity and CKD with different adjustments for 
reciprocal adiposity and mediators in men 
 
CKD (n=18,034, 6.4%) is defined as long-term renal replacement therapy, eGFRcys-cr<60 mL/min/1.73m² or urinary albumin:creatinine ratio  mg/mmol.  
ORs (95% CI) of any CKD per 0.06 increase in waist-to-hip ratio or per 5 kg/m² increase in BMI are shown. The increment for both adiposity measures equalled 1.10 × measurement-error corrected standard deviation (SD).  
ng, physical activity at baseline. 
he genetic analyses, confounder adjusted model was adjusted for top 40 principal components and genotyping array; other models were additionally adjusted for the genetic effects of the adiposity-selected SNPs on reciprocal 
adiposity (waist-to-hip ratio adjusted for BMI or vice versa), type 2 diabetes, or BP (systolic/diastolic BP).  





 Waist-to-hip ratio (per 0.06 higher level)  BMI (per 5 kg/m2 higher level) 
 Conventional    Conventional   
Adjustments OR (95% CI) 
2   
(% reduction) 
OR (95% CI) 
2   
(% reduction) 
 OR (95% CI) 
2   
(% reduction) 
OR (95% CI) 
2   
(% reduction) 
Confounder adjusted (Aim 1) 2.05 (1.95, 2.15) 851.8 (ref) 1.55 (1.36, 1.76) 44.0 (ref)  1.83 (1.77, 1.90) 999.4 (ref) 1.74 (1.56, 1.94) 104.5 (ref) 
+ Diabetes alone 1.77 (1.68, 1.86) 508.7 (40%) 1.26 (1.09, 1.46) 9.7 (78%)  1.61 (1.54, 1.67) 567.4 (43%) 1.52 (1.36, 1.71) 49.8 (52%) 
+ BP alone 2.01 (1.92, 2.11) 801.8 (6%) 1.45 (1.26, 1.67) 27.7 (37%)  1.80 (1.73, 1.87) 920.0 (8%) 1.60 (1.43, 1.80) 62.2 (41%) 
+ Both (Aim 2) 1.72 (1.63, 1.81) 453.4 (47%) 1.23 (1.05, 1.43) 6.9 (84%)  1.55 (1.49, 1.61) 479.2 (52%) 1.46 (1.29, 1.65) 34.7 (67%) 
          
Adiposity adjusted (Aim 3) 1.60 (1.51, 1.68) 301.5 (ref) 1.36 (1.15, 1.61) 12.8 (ref)  1.56 (1.49, 1.62) 442.8 (ref) 1.56 (1.32, 1.83) 28.7 (ref) 
+ Diabetes alone 1.47 (1.40, 1.56) 201.4 (33%) 1.17 (0.98, 1.40) 3.2 (75%)  1.41 (1.35, 1.47) 252.3 (43%) 1.43 (1.21, 1.68) 17.7 (38%) 
+ BP alone  1.60 (1.52, 1.69) 302.0 (0%) 1.30 (1.09, 1.55) 8.6 (33%)  1.53 (1.47, 1.59) 403.3 (9%) 1.48 (1.26, 1.75) 21.9 (24%) 
+ Both (Aim 4) 1.47 (1.40, 1.55) 198.6 (34%) 1.15 (0.96, 1.38) 2.3 (82%)   1.37 (1.31, 1.43) 206.8 (53%) 1.39 (1.17, 1.64) 14.7 (49%) 
Supplemental table 3b: Conventional and genetic associations between adiposity and CKD with different adjustments for 
reciprocal adiposity and mediators in women 
 
CKD (n=18,034, 6.4%) is defined as long-term renal replacement therapy, eGFRcys-cr<60 mL/min/1.73m² or urinary albumin:creatinine ratio  mg/mmol.  
ORs (95% CI) of any CKD per 0.06 increase in waist-to-hip ratio or per 5 kg/m² increase in BMI are shown. The increment for both adiposity measures equalled 1.10 × measurement-error corrected standard deviation (SD).  
ng, physical activity at baseline. 
he genetic analyses, confounder adjusted model was adjusted for top 40 principal components and genotyping array; other models were additionally adjusted for the genetic effects of the adiposity-selected SNPs on reciprocal 
adiposity (waist-to-hip ratio adjusted for BMI or vice versa), type 2 diabetes, or BP (systolic/diastolic BP).  





 Waist-to-hip ratio (per 0.06 higher level)  BMI (per 5 kg/m2 higher level) 
 Conventional    Conventional   
Adjustments OR (95% CI) 
2   
(% reduction) 
OR (95% CI) 
2   
(% reduction) 
 OR (95% CI) 
2   
(% reduction) 
OR (95% CI) 
2   
(% reduction) 
Confounder adjusted (Aim 1) 1.46 (1.40, 1.52) 308.5 (ref) 1.20 (1.11, 1.30) 20.0 (ref)  1.45 (1.40, 1.49) 581.7 (ref) 1.33 (1.22, 1.46) 38.6 (ref) 
+ Diabetes alone 1.33 (1.27, 1.38) 164.5 (47%) 1.13 (1.03, 1.25) 6.1 (69%)  1.35 (1.31, 1.40) 371.0 (36%) 1.23 (1.11, 1.36) 16.6 (57%) 
+ BP alone 1.38 (1.32, 1.44) 221.2 (28%) 1.14 (1.05, 1.24) 9.0 (55%)  1.38 (1.34, 1.42) 421.8 (27%) 1.27 (1.15, 1.40) 21.8 (44%) 
+ Both (Aim 2) 1.25 (1.20, 1.31) 101.6 (67%) 1.10 (1.00, 1.22) 3.5 (82%)  1.28 (1.24, 1.32) 236.7 (59%) 1.20 (1.07, 1.33) 10.7 (72%) 
          
Adiposity adjusted (Aim 3) 1.30 (1.24, 1.36) 133.9 (ref) 1.15 (1.06, 1.25) 10.6 (ref)  1.35 (1.31, 1.40) 348.6 (ref) 1.28 (1.14, 1.43) 18.0 (ref) 
+ Diabetes alone 1.22 (1.17, 1.28) 74.2 (45%) 1.12 (1.01, 1.23) 4.6 (57%)  1.29 (1.25, 1.33) 239.8 (31%) 1.22 (1.08, 1.37) 11.1 (39%) 
+ BP alone  1.27 (1.22, 1.33) 112.2 (16%) 1.10 (1.01, 1.21) 4.8 (55%)  1.30 (1.26, 1.34) 253.1 (27%) 1.23 (1.09, 1.38) 11.9 (34%) 
+ Both (Aim 4) 1.19 (1.14, 1.25) 57.6 (57%) 1.09 (0.98, 1.20) 2.7 (75%)   1.23 (1.19, 1.27) 153.1 (56%) 1.19 (1.05, 1.34) 7.8 (57%) 
Supplemental table 4: Conventional and genetic associations between adiposity and CKD, by diabetes status with and without adjustment for blood 
pressure 
 
CKD (18,034, 6.4%) is defined as long-term renal replacement therapy, eGFRcys-cr<60 mL/min/1.73m2 mmol. 
ORs (95% CI) of any CKD per 0.06 increase in waist-to-hip ratio or per 5 kg/m2 increase in BMI are shown. The increment for both adiposity measures equalled 1.10 × measurement-error corrected standard deviation (SD). 
confounders include age, ethnicity, education, region, deprivation index, smoking, physical activity at baseline. 
r models were additionally adjusted for the genetic effects of the adiposity-selected SNPs on BP (systolic/diastolic BP). 
BMI: body mass index; BP: blood pressure; CI: confidence interval; CKD: chronic kidney disease; eGFR: estimated glomerular filtration rate; HbA1c: glycosylated hemoglobin; OR: odds ratio. 










Population Definition CKD at 
baseline 
Adjustments Waist-to-hip ratio (per 0.06 higher level) BMI (per 5 kg/m2 higher level) 
    
OR (95% CI) 2 (% 
reduction) 
OR (95% CI) 2 (% 
reduction) 
OR (95% CI) 2 (% 
reduction) 










1.52 (1.41-1.65) 106 (ref) 1.34 (1.10-1.64) 9 (ref) 1.48 (1.40-1.57) 178 (ref) 1.36 (1.18-1.56) 19 (ref) 







1.44 (1.23-1.69) 20 (ref) 1.05 (0.72-1.53) 0.1 (ref) 1.39 (1.27-1.53) 47 (ref) 1.24 (0.95-1.63) 2 (ref) 
+ BP alone 1.39 (1.18-1.63) 16 (20%) 1.09 (0.73-1.64) 0.2 (**) 1.35 (1.23-1.48) 38 (19%) 1.21 (0.90-1.64) 2 (**) 
No baseline 
diabetes  





1.50 (1.45-1.56) 465 (ref) 1.14 (1.05-1.23) 10 (ref) 1.43 (1.39-1.47) 662 (ref) 1.30 (1.19-1.41) 38 (ref) 
+ BP alone 1.42 (1.37-1.48) 346 (26%) 1.08 (0.99-1.17) 3 (72%) 1.36 (1.32-1.40) 468 (29%) 1.21 (1.10-1.33) 16 (56%) 





















GRS: genetic risk score; GWAS: genome-wide association studies; LD: linkage disequilibrium; MAF: minor allele frequency; SNP: single nucleotide 
polymorphisms. 
Variance explained (%) of waist-to-hip ratio in UK Biobank was shown in brackets, the 394 SNPs included in waist-to-hip ratio GRS explained 2.53% and 
5.29% of variance in men and women, respectively. 
F statistics of GRS was 28.31. 
* 115 SNPs of the 394 SNPs were associated with BMI at p<5×10-9. 
 
Reference: 
1. Pulit, SL, Stoneman, C, Morris, AP, Wood, AR, Glastonbury, CA, Tyrrell, J, Yengo, L, et al. : Meta-analysis of genome-wide association studies for body fat 
distribution in 694 649 individuals of European ancestry.  Human molecular genetics 28: 166-174, 2019. 
 
 
    
   
   
 
  
      
     









   
 
   
  
      
   


























BMI: body mass index; GRS: genetic risk score; GWAS: genome-wide association studies; LD: linkage disequilibrium; MAF: minor allele frequency; SNP: 
single nucleotide polymorphisms. 
Variance explained (%) of BMI in UK Biobank was shown in brackets, the 773 SNPs included in BMI GRS explained 6.14% and 5.54% of variance in men and 
women, respectively. 
F statistics of GRS was 23.63. 
* 105 of the 773 SNPs were associated with waist-to-hip ratio at p<5×10-9. 
 
Reference: 
1. Yengo, L, Sidorenko, J, Kemper, KE, Zheng, Z, Wood, AR, Weedon, MN, et al.: Meta-analysis of genome-wide association studies for height and body mass 
index in approximately 700000 individuals of European ancestry. Human molecular genetics 27: 3641-3649, 2018. 
    
     
   
  
     
    
    
    
  
       
    
   
  
    
  
   
  
      
   
  
      
Supplemental figure 3: Conventional and genetic associations between adiposity measures 











OR (95% CI) per 0.06 increase in waist−to−hip ratio:
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Women:  1.46 (1.40, 1.52)
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OR (95% CI) per 0.06 increase in waist−to−hip ratio:
Men:  1.55  ( 1.36  −  1.76 )
Women:  1.20  ( 1.11  −  1.30 )




15 20 25 30 35 40
OR (95% CI) per 5 kg/ m2 increase in BMI:
Men:  1.74  ( 1.56  −  1.94 )
Women:  1.33  ( 1.22  −  1.46 )
 CKD (n=18,034, 6.4%) is defined as long−term renal replacement therapy, eGFRcys−cr <60 mL/min/1.73 m
2 or urinary albumin:creatinine ratio ≥ 3 mg/mmol.
 Conventional epidemiological analyses: ORs (95% CI) of any CKD by fifths of measured waist−to−hip ratio and BMI are shown. Model was adjusted for confounders (age, education, region, 
 deprivation index, smoking, physical activity). 
 Genetic epidemiological analyses: OR (95% CI) of any CKD by fifths of GRS for increasing waist−to−hip ratio and BMI are shown. Model was adjusted for top 40 principal components and 
 genotyping array.
 BMI: body mass index; CI: confidence interval; CKD: chronic kidney disease; eGFRcys−cr : estimated glomerular filtration rate calculated from both serum cystatin C and creatinine.
 GRS: genetic risk score; OR: odds ratio.
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Supplemental figure 4: Conventional and genetic associations between adiposity measures and CKD using GRS with exclusions of






Aim 1: To quantify "causal" association
1.1 Confounder adjusted (conventional)
1.2 Mendelian randomisation with basic adjustments (genetic)
Aim 2: To assess mediation
2.1 Model 1.1 adjusted for mediators (conventional)
2.2 Model 1.2 adjusted for mediators (genetic)
1.69 (1.64, 1.74) 1051
1.43 (1.39, 1.48) 466
1.28 (1.20, 1.38) 48
1.14 (1.05, 1.24) 9.1
0.5 1 1.5 2
OR (95% CI) OR (95% CI)
OR (95% CI)
per 5 kg m2 higher
BMI χ2
1.58 (1.55, 1.62) 1487
1.38 (1.35, 1.41) 660
1.49 (1.39, 1.59) 129
1.30 (1.20, 1.41) 40
0.5 1 1.5 2
 CKD (n=18,034, 6.4%) is defined as long−term renal replacement therapy, eGFRcys−cr <60 mL/min/1.73 m
2 or urinary albumin:creatinine ratio ≥ 3 mg/mmol.
 ORs (95% CI) of any CKD per 0.06 increase in waist−to−hip ratio or per 5 kg/ m2 increase in BMI with corrections for measurement error are shown.
 Adjustment for mediators were based on measures of baseline diabetes and systolic/diastolic blood pressure in conventional analyses, and the genetic effects of the adiposity−selected SNPs on type 2 diabetes and
 systolic/diastolic blood pressure in genetic analyses.
 BMI: body mass index; CI: confidence interval; CKD: chronic kidney disease;  eGFRcys−cr : estimated glomerular filtration rate calculated from both serum cystatin C and creatinine.
 OR: odds ratio; SNP: single nucleotide polymorphism.
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Aim 1: To quantify "causal" association
1.1 Confounder adjusted (conventional)
1.2 Mendelian randomisation with basic adjustments (genetic)
Aim 2: To assess mediation
2.1 Model 1.1 adjusted for mediators (conventional)
2.2 Model 1.2 adjusted for mediators (genetic)
LOW KIDNEY FUNCTION (eGFR<60 mL/min/1.73 m2 )
Aim 1: To quantify "causal" association
1.1 Confounder adjusted (conventional)
1.2 Mendelian randomisation with basic adjustments (genetic)
Aim 2: To assess mediation
2.1 Model 1.1 adjusted for mediators (conventional)
2.2 Model 1.2 adjusted for mediators (genetic)
1.58 (1.52, 1.64) 607
1.28 (1.18, 1.38) 37
1.29 (1.25, 1.34) 178
1.14 (1.03, 1.25) 6.7
1.96 (1.85, 2.07) 572
1.32 (1.17, 1.48) 21
1.79 (1.69, 1.90) 410
1.19 (1.03, 1.37) 5.4
0.5 1 1.5 2
OR (95% CI) OR (95% CI)
OR (95% CI)
per 5 kg m2 higher
BMI χ2
1.45 (1.41, 1.49) 717
1.36 (1.25, 1.47) 57
1.20 (1.17, 1.24) 157
1.19 (1.08, 1.31) 13
1.87 (1.80, 1.95) 939
1.84 (1.64, 2.08) 103
1.81 (1.73, 1.88) 765
1.63 (1.41, 1.87) 46
0.5 1 1.5 2
 Any albuminuria (n=13,413, 4.8%) is defined as urinary albumin:creatinine ratio ≥ 3 mg/mmol.
 eGFR<60 mL/min/1.73 m2 (n=5,812, 2.1%) is defined as long−term renal replacement therapy or eGFRcys−cr <60 mL/min/1.73 m
2 .
 OR (95% CI) of any albuminuria per 0.06 increase in waist−to−hip ratio or per 5 kg/ m2 increase in BMI with corrections for measurement error are shown.
 Adjustment for mediators were based on measures of baseline diabetes and systolic/diastolic blood pressure in conventional analyses, and the genetic effects of the adiposity−selected SNPs on type 2 diabetes and
 systolic/diastolic blood pressure in genetic analyses.
 BMI: body mass index; CI: confidence interval; CKD: chronic kidney disease;  eGFRcys−cr : estimated glomerular filtration rate calculated from both serum cystatin C and creatinine.
 OR: odds ratio; SNP: single nucleotide polymorphism.
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CKD ( eGFRcr <60 mL/min/1.73 m
2 OR ALBUMINURIA)
Aim 1: To quantify "causal" association
1.1 Confounder adjusted (conventional)
1.2 Mendelian randomisation with basic adjustments (genetic)
Aim 2: To assess mediation
2.1 Model 1.1 adjusted for mediators (conventional)
2.2 Model 1.2 adjusted for mediators (genetic)
CKD ( eGFRcys <60 mL/min/1.73 m
2 OR ALBUMINURIA)
Aim 1: To quantify "causal" association
1.1 Confounder adjusted (conventional)
1.2 Mendelian randomisation with basic adjustments (genetic)
Aim 2: To assess mediation
2.1 Model 1.1 adjusted for mediators (conventional)
2.2 Model 1.2 adjusted for mediators (genetic)
1.56 (1.51, 1.61) 753
1.23 (1.15, 1.32) 36
1.33 (1.29, 1.38) 298
1.11 (1.02, 1.21) 6.1
1.80 (1.75, 1.85) 1597
1.32 (1.24, 1.41) 80
1.56 (1.51, 1.61) 862
1.15 (1.07, 1.24) 13
0.5 1 1.5 2
OR (95% CI) OR (95% CI)
OR (95% CI)
per 5 kg m2 higher
BMI χ2
1.45 (1.42, 1.49) 968
1.40 (1.34, 1.46) 247
1.27 (1.24, 1.30) 356
1.11 (1.00, 1.24) 3.6
1.78 (1.74, 1.81) 2815
1.61 (1.52, 1.72) 229
1.59 (1.55, 1.62) 1668
1.40 (1.30, 1.51) 81
0.5 1 1.5 2
 CKD is defined as long−term renal replacement therapy, eGFR<60 mL/min/1.73 m2 or urinary albumin:creatinine ratio ≥ 3 mg/mmol, with 17,987 (6.4%) when eGFRcr used and 22,790 (8.1%) when eGFRcys used.
 OR (95% CI) of any CKD per 0.06 increase in waist−to−hip ratio or per 5 kg/ m2 increase in BMI with corrections for measurement error are shown.
 Adjustment for mediators were based on measures of baseline diabetes and systolic/diastolic blood pressure in conventional analyses, and the genetic effects of the adiposity−selected SNPs on type 2 diabetes and
 systolic/diastolic blood pressure in genetic analyses.
 BMI: body mass index; CI: confidence interval; CKD: chronic kidney disease;  eGFRcr : estimated glomerular filtration rate calculated from serum creatinine.
  eGFRcys : estimated glomerular filtration rate calculated from serum cystatin C; OR: odds ratio; SNP: single nucleotide polymorphism.
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Supplemental figure 7: Genetic associations between adiposity measures and CKD
using two−sample Mendelian Randomisation
Outcome Increment
OR (95% CI) 
per incremental increase 
in adiposity p value
Waist−to−hip ratio
BMI
1.45 (1.33, 1.57) <0.01IVW with iterative weighting 0.06
1.45 (1.33, 1.57) <0.01Outlier corrected IVW (Modified Q statistic)
1.44 (1.31, 1.58) <0.01MR−PRESSO
1.29 (1.10, 1.53) <0.01MR−Egger with iterative weighting
1.37 (1.18, 1.60) <0.01Weighted median
1.50 (1.40, 1.60) <0.01IVW with iterative weighting 5 kg/ m2 
1.50 (1.40, 1.60) <0.01Outlier corrected IVW (Modified Q statistic)
1.51 (1.41, 1.61) <0.01MR−PRESSO
1.28 (1.13, 1.45) <0.01MR−Egger with iterative weighting
1.53 (1.36, 1.71) <0.01Weighted median
1 2 3
OR (95% CI)
 CKD (n=18,034, 6.4%) is defined as long−term renal replacement therapy, eGFRcys−cr <60 mL/min/1.73 m
2 or urinary albumin:creatinine ratio ≥ 3 mg/mmol.
ORs (95% CI) of any CKD per 0.06 increase in waist−to−hip ratio or per 5 kg/ m2 increase in BMI using two−sample Mendelian Randomisation methods are shown.
BMI: body mass index; CI: confidence interval; CKD: chronic kidney disease; 
 eGFRcys−cr : estimated glomerular filtration rate calculated from both serum cystatin C and creatinine; OR: odds ratio.
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